ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Recurrence
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near Chicago, IL, USA:

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Best Available Therapy (BAT)

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Evanston, Illinois, United States and 21 other locations

Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments. (TEAAMS)

immediate and sustained improvement in walking dysfunction, symptoms, and health-related quality of life (HRQOL) among African-Americans with MS...

Enrolling
Multiple Sclerosis
Behavioral: Guidelines for Exercise in Multiple Sclerosis (GEMS)
Behavioral: FLEX Stretching and Toning Program
University of Illinois
University of Illinois

Chicago, Illinois, United States

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson'...

Enrolling
Adjustment Disorder
Drug: RE104 for Injection

Phase 2

Reunion Neuroscience

Chicago, Illinois, United States and 27 other locations

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.2. study the pre- a...

Enrolling
Multiple Sclerosis (MS) - Relapsing-remitting
Multiple Sclerosis
Drug: Ublituximab

Phase 4

Northwestern University
Northwestern University

Chicago, Illinois, United States

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis (KATHAROS)

This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS...

Active, not recruiting
Multiple Sclerosis
Drug: Ofatunumab

Phase 4

Novartis
Novartis

Winfield, Illinois, United States and 14 other locations

Locations recently updated

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis (REMASTER)

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis...

Enrolling
Secondary Progressive Multiple Sclerosis (SPMS)
Drug: Remibrutinib (blinded)
Drug: Placebo

Phase 3

Novartis
Novartis

Chicago, Illinois, United States and 207 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Chicago, Illinois, United States and 200 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

Phase 3

Novartis
Novartis

Merrillville, Indiana, United States and 223 other locations

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis (Frexcite)

of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: MRI contrast-enhancing preparations

Phase 3

Sanofi
Sanofi

Northbrook, Illinois, United States of America and 31 other locations

Locations recently updated

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple...

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib oral treatment
Drug: Ocrelizumab

Phase 3

Novartis
Novartis

Chicago, Illinois, United States and 105 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems